Pixantrone - redOrbit

Cell Therapeutics' Pixuvri® Phase 3 Clinical Trial Results Published in The Lancet Oncology

2012-05-30 22:20:31

SEATTLE, May 31, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that results from its PIX301 phase 3 clinical trial of Pixuvri® (pixantrone) have

Cell Therapeutics' Pixuvri® Approved in European Union as Monotherapy to Treat Adult Patients with Multiply Relapsed or Refractory Aggressive Non-Hodgkin B-Cell Lymphomas

2012-05-10 10:25:05

SEATTLE, May 10, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.("CTI") (Nasdaq and MTA: CTIC) today announced that it has received conditional marketing authorization

Cell Therapeutics, Inc. (CTI) Reports Fourth Quarter and Year-End Financial Results and Milestones

2012-03-07 00:30:00

SEATTLE, March 7, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.

European Medicines Agency's Committee For Medicinal Products For Human Use Issues Positive Opinion For Conditional Approval On Marketing Authorization Application For Pixuvri(TM)

2012-02-17 06:34:00

SEATTLE, Feb. 17, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.

Cell Therapeutics Withdraws New Drug Application for Pixuvri(TM) and Plans to Resubmit in 2012

2012-01-30 00:30:00

SEATTLE, Jan. 30, 2012 /PRNewswire/ -- Cell Therapeutics, Inc.

News - Pixantrone

Breaking News

Streaming Video

Images and Photos

Space Exploration

Science and Research

Technology

My Health